<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="belong to several virus families, and although many features of" exact="infection" post="with these diverse viruses are shared, some have unique"/>
 <result pre="belong to several virus families, and although several features of" exact="infection" post="with these diverse viruses are shared, some have unique"/>
 <result pre="receptor are only present in the upper respiratory tract, then" exact="infection" post="is likely to be limited to rhinitis (characterized by"/>
 <result pre="it is 4.5â€&quot;5.8Â days (Lauer etÂ al., 2020). Productive viral" exact="infection" post="of respiratory epithelial cells results in clinical symptoms and"/>
 <result pre="bronchiolitis, involving the smaller distal airways, is characteristic of RSV" exact="infection" post="in young infants and presents with wheezing. Pneumonia occurs"/>
 <result pre="in young infants and presents with wheezing. Pneumonia occurs when" exact="infection" post="and inflammation involve the alveoli and lung parenchyma and"/>
 <result pre="lungs (pneumonia). The best example of this is secondary bacterial" exact="infection" post="caused by Streptococcus pneumoniae or Staphylococcus aureus following influenza"/>
 <result pre="Response to Respiratory Viruses The immune system responds to viral" exact="infection" post="with cellular and humoral (antibodies, complement, and antimicrobial peptides)"/>
 <result pre="phospholipids from invading pathogens. DAMPs and PAMPs released during initial" exact="infection" post="and lysis of pneumocytes (surface epithelial cells of the"/>
 <result pre="H1N1 influenza. What Happens in COVID-19? After an incubation period," exact="infection" post="progresses from the pre-symptomatic stage (1â€&quot;3Â days) through symptomatic"/>
 <result pre="infection progresses from the pre-symptomatic stage (1â€&quot;3Â days) through symptomatic" exact="infection" post="(2â€&quot;4Â weeks) to a prolonged post-symptomatic or recovery stage"/>
 <result pre="). The spectrum of disease with SARS-CoV-2 ranges from asymptomatic" exact="infection" post="to severe, often fatal disease. Patients with mild disease"/>
 <result pre="and TÂ cells are detected within the first week of" exact="infection" post="in mild to moderate COVID-19 cases (Thevarajan etÂ al.,"/>
 <result pre="proteins that target specific parts of the immune system. Severe" exact="infection" post="and complications occur more frequently in males and those"/>
 <result pre="procalcitonin (Gandhi etÂ al., 2020). The pathogenesis of severe SARS-CoV-2" exact="infection" post="is complex, and we are still learning about it"/>
 <result pre="the nose and lungs are endowed with ACE2, which facilitates" exact="infection" post="of the respiratory tract. However, ACE2 is also expressed"/>
 <result pre="endothelium, heart, gut, and kidneys, making these organs susceptible to" exact="infection" post="by the virus. A prominent feature of severe SARS-CoV-2"/>
 <result pre="of severe SARS-CoV-2 infections is the cytokine release syndrome. SARS-CoV-2" exact="infection" post="of respiratory epithelial cells activates monocytes, macrophages, and dendritic"/>
 <result pre="of IL-6 antagonists such as tocilizumab, sarilumab, and siltuximab for" exact="treatment" post="of severe COVID-19 disease (Moore and June, 2020). In"/>
 <result pre="in other viral pneumonias. The benefit of anticoagulants in the" exact="treatment" post="of severe COVID-19 disease is therefore of great interest."/>
 <result pre="is becoming clear that the pathogenetic cascade triggered by SARS-CoV-2" exact="infection" post="damages many organs in the body, from the kidneys"/>
 <result pre="activity against SARS-CoV-2. The fastest path to finding an effective" exact="treatment" post="may be to repurpose licensed drugs that are approved"/>
 <result pre="interim analysis from a large international clinical trial revealed that" exact="treatment" post="with remdesivir reduced the duration of hospitalization by an"/>
 <result pre="is now available, and the drug has been approved for" exact="treatment" post="of COVID-19 in the US (Beigel et al., 2020)."/>
 <result pre="trials alone or as an adjunct to antiviral drugs for" exact="treatment" post="of severe disease (FigureÂ 2). Antibodies can also be"/>
 <result pre="disease (FigureÂ 2). Antibodies can also be administered to prevent" exact="infection" post="in individuals who are known to be at risk"/>
 <result pre="in individuals who are known to be at risk of" exact="infection" post="(FigureÂ 2), referred to as immunoprophylaxis. The optimal timing"/>
 <result pre="the respiratory tract after binding distinct cell surface receptors, and" exact="infection" post="rapidly triggers innate immune responses. However, viruses employ several"/>
 <result pre="GroupThe effectiveness of convalescent plasma and hyperimmune immunoglobulin for the" exact="treatment" post="of severe acute respiratory infections of viral etiology: a"/>
</results>
